Patients receiving their first kidney transplant are at 18% higher risk for newly diagnosed atrial fibrillation if they were on hemodialysis rather than peritoneal dialysis prior to transplantation, a study found.
The kidney stone rate appears to have risen among kidney transplant recipients over the past 2 decades, according to investigators.
Currently, there is no approved therapy for calciphylaxis.
Adverse events rates have been rising over time among patients receiving dialysis, investigators reported.
The rate of esophageal and gastric erosions among patients on dialysis eligible for anemia treatment was approximately 49 events per 100 patient-years, investigators report.
Patients receiving peritoneal dialysis rather than hemodialysis or both modalities have the lowest rate of ESA hyporesponse.
Patients with persistent ESA hyporesponse had especially high rates of adverse events.
Upward trend follows debut of the federal End-Stage Renal Disease Treatment Choices payment model in January 2021.
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
Black patients without high-risk APOL1 alleles did not have higher risks for kidney failure.